Latest Announcements

Alzheimer's Disease, Parkinson's Disease, Investor Announcement

Prana’s Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer’s & Parkinson’s Diseases

Prana today announced a scientific presentation demonstrating pre-clinical evidence for Prana’s PBT434 as a first-in-class disease modifying therapy for the treatment of Parkinsonian movement disorders that will be featured at the 13th International Conference for Alzheimer’s and Parkinson’s Diseases in Vienna from 29 March 2 April 2017.


Investor Announcement

Prana Business Update

Prana today provided a business update on its development portfolio of potential neurodegenerative treatments.


Movement disorders expert Professor Ira Shoulson joins Prana Biotechnology's Board of Directors

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"